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233Excessive Atrial Ectopy and
Short Atrial Runs Increase the Risk of
Stroke Beyond Incident Atrial FibrillationABSTRACTBACKGROUND Approximately 30% of ischemic strokes have an unknown cause. Increased atrial ectopy (AE) increases
the risk of atrial ﬁbrillation (AF), but the risk of stroke in patients with increased AE is unknown.
OBJECTIVES This study aimed to examine whether increased AE and short atrial runs increase the risk of stroke
beyond incident AF.
METHODS Data were collected during a 15-year follow-up of the Copenhagen Holter Study cohort with 678 men
and women between 55 and 75 years of age, with no earlier history of cardiovascular disease, stroke, or AF. Study
subjects underwent 48-h ambulatory electrocardiography, fasting blood tests, and clinical examination. Excessive
supraventricular ectopic activity (ESVEA) was deﬁned as the presence of either $30 premature atrial contractions
(PACs)/hour daily or any runs of $20 PACs.
RESULTS Ninety-nine subjects (15%) demonstrated ESVEA. After adjusting for baseline risk factors, ESVEA was
associated with ischemic stroke when censoring subjects at time of AF (hazard ratio [HR]: 1.96; 95% conﬁdence interval
[CI]: 1.10 to 3.49) or when modeling AF as a time-varying exposure (HR: 2.00; 95% CI: 1.16 to 3.45). Among subjects
with ESVEA who developed a stroke, 14.3% had diagnosed AF before their stroke. The incidence of stroke in subjects
with ESVEA and a CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus,
previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score of $2 was 2.4% per year,
comparable to the risk observed in AF. In day-to-day analysis, ESVEA was a consistent ﬁnding.
CONCLUSIONS ESVEA was associated with an increased risk of ischemic stroke beyond manifest AF in this middle-
aged and older population. Stroke was more often the ﬁrst clinical presentation, rather than AF, in these study
subjects. (J Am Coll Cardiol 2015;66:232–41) © 2015 by the American College of Cardiology Foundation.SEE PAGE 242
D espite meticulous research for the etiologyof ischemic stroke, 25% to 30% of strokesremain unexplained and are consequently
labelled cryptogenic (1,2). Occult atrial ﬁbrillation
(AF) is thought to be partly responsible for this phe-
nomenon (3–9). However, paroxysmal AF often goes
undetected as a result of the heterogeneous presen-
tation with no symptoms, a short duration, and
episodic runs (10). This issue has prompted new
strategies to detect incident AF, especially through
prolonged electrocardiogram (ECG) monitoring (3–
9). In recent years increased atrial ectopy (AE) has
been shown to be associated with a higher risk of
AF (11–15). Some studies have reported an associa-
tion with stroke as well, but the increased risk is
thought to be secondary to subsequent AF (11,12).
The risk of stroke in persons with increased AE is
unknown, and it is also not known whether these
persons will present with clinical AF before having
a stroke. This study investigated the independentassociation between increased AE and ischemic
stroke.We hypothesized that excessive supraventricular
ectopic activity (ESVEA) independently increases the
risk of ischemic stroke, comparable to AF.
METHODS
COPENHAGEN HOLTER STUDY. The Copenhagen
Holter Study included patients enrolled between April
1998 and June 2000. Follow-up was performed in 2013,
thus including up to 15-years of follow-up in some pa-
tients. The aim of the follow-up study was to address
the value of 48-h Holter recording in relation to other
risk factors, in the assessment of future adverse events
in terms of AF, ischemic stroke, and mortality in
middle-aged and older men and women. Information
about the study protocol and the selection procedures
ABBR EV I A T I ON S
AND ACRONYMS
AE = atrial ectopy
AF = atrial ﬁbrillation
CHA2DS2-VASc = congestive
heart failure, hypertension, age
75 years or older, diabetes
mellitus, previous stroke or
transient ischemic attack,
vascular disease, age 65 to 74
years, female
ECG = electrocardiogram
ESVEA = excessive
supraventricular ectopic
activity
NT-proBNP = N-terminal
prohormone of brain natriuretic
peptide
PAC = premature atrial
contraction
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234were published previously (16). Brieﬂy, all men
55 years and allmen andwomen 60, 65, 70, and
75 years of age (n ¼ 2,969) who were living
within 2 deﬁned postal regions in the city of
Copenhagen were contacted with a question-
naire regarding cardiovascular risk factors,
medication use, and medical history. All
responding individuals with>1 risk factor, and
60% of randomly selected subjects with 0 to 1
risk factors were invited to follow-up consist-
ing of a physician-based questionnaire, phys-
ical examination, laboratory testing, ECG and
48-h continuous ECG recording. Subjects with
current or past AF, manifest ischemic heart
disease, congestive heart failure, valvular
heart disease, congenital heart disease, an-
gina pectoris, stroke, cancer, or other life-
threatening conditions were excluded. This
resulted in 678 participants who underwentfasting laboratory tests, a physical examination with
anthropometric measurements, and up to 48 h of
continuous Holter monitoring. Holter recording was
performed with the use of 2-channel SpaceLabs tape
recorders (9025, SpaceLabs, Inc., Redwood, Washing-
ton). Recordings were evaluated and interpreted by
trained personnel, and the interobserver variability
shows kappa values between 0.91 and 0.94 (17). Median
value of technically acceptable recording was 44.1 h,
and ﬁrst and third quartiles (Q1, Q3) were 41.4 to 45.5 h;
98% of the subjects had >24 h of recording.
DEFINITIONS. In accordance with previous deﬁni-
tions (11), 2 classes of supraventricular arrhythmias
were investigated: premature atrial contractions
(PACs) and runs of $3 PACs. The basis of veriﬁcation
of PAC consisted of 3 criteria: prematurity, post-
contraction pause, and morphology. The coupling
interval to the preceding QRS complex had to be#70%
of the mean RR interval of basic rhythm before the
event. QRS complexes had a length of <0.11 s unless
aberration was assumed. The post-contraction pause
had to be noncompensatory. Frequency of PACs and
length of runs of PACs were analyzed as both contin-
uous and dichotomized variables. Assuming that PACs
had to be excessive to increase adverse events, the
cutoff value was set at the top decile in both frequency
of PACs and length of runs of PACs. Accordingly,
ESVEA was deﬁned as $30 PACs/h or any episode of
runs of $20 PACs.
FOLLOW-UP. Events of stroke, incident AF, and death
were retrieved from the national central patient reg-
istry and from discharge letters and were validated by
reviewing patients’ ﬁles. The diagnosis of stroke was
made on the basis of clinical ﬁndings with a conﬁrmeddiagnosis by computed tomography or magnetic
resonance imaging. All nonischemic strokes were
excluded in the analysis for this paper. The diagnosis of
incident AF was veriﬁed with documentation in the
form of ECG, telemetry, or both, from patient records.
All medications were registered at baseline, and no
participants were receiving treatment with anticoag-
ulants. Endpoints included were stroke and a com-
bined endpoint of all-cause mortality or ﬁrst event of
stroke.
ETHICS. All participants provided written informed
consent. The regional ethical committee of Copen-
hagen and Frederiksberg approved the study. The
study is in compliance with the Helsinki Declaration.
STATISTICAL ANALYSIS. Mean  SD is reported for
continuous variables with a normal distribution. Data
that are not normally distributed are presented as
median with interquartile ranges. Pearson chi-square
test, Fisher exact test, 2-tailed Student t test, and
Wilcoxon rank-sum test (Mann-Whitney U test) were
used for the comparison of groups as appropriate.
Kaplan-Meier survival function was used to compare
event-free survival in different groups according to
ESVEA, and the log rank test (Mantel-Cox test) was
used to test for equality of the survivor function.
Cox proportional hazards model estimated the
hazard of ESVEA in relation to the endpoint of stroke,
or the composite endpoint of death or stroke. To esti-
mate the effect of incident AF on our primary end-
points, we used a Cox regressionmodel with censoring
at time of AF and another model with AF as a time-
varying exposure. Furthermore, the association be-
tween ESVEA and stroke was assessed using the
competing risk proportional subhazard model by the
method of Fine and Gray (18), in which AF and “dead”
were modeled as competing risks to the endpoint of
stroke. The selection of potentially confounding co-
variates in Cox regression models and competing risk
models was made on the basis of existing knowledge
about their relationship with ischemic stroke and by
risk factors associated with ischemic stroke at base-
line. In further exploration of the data, we added
ESVEA to a Cox proportional hazard model with the
Framingham Stroke Risk Score (19) as a continuous
variable. Improvement of the model with entrance of
ESVEA was assessed by a likelihood ratio test.
The assumption of linearity for continuous cova-
riates was tested and conﬁrmed. The proportional
hazard assumption was tested for each of the Cox
models on the basis of Schoenfeld residuals. To eval-
uate the stability of ESVEA,we calculated kappa values
of having >30 PACs/h on 2 separate days. Data on the
daily variation of PACs were available for analysis in
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235644 subjects (95% of the population). Any 2-tailed
p value <0.05 was considered signiﬁcant. Statistical
analysis was performed using STATA version 13.0
(StataCorp, College Station, Texas).
RESULTS
STUDY POPULATION. A total of 678 patients partici-
pated in this study. Median follow-up was 14.4 years,
and no patients were lost to follow-up. The baseline
characteristics of the population with and without
stroke in the follow-up and ESVEA at baseline are
shown in Table 1. Subjects who had a stroke were likely
to be older, smokers, with higher blood pressure, a
higher CHA2DS2-VASc (congestive heart failure, hy-
pertension, age 75 years or older, diabetes mellitus,
previous stroke or transient ischemic attack, vascular
disease, age 65 to 74 years, female) score, and higher
N-terminal prohormone of brain natriuretic peptide
(NT-proBNP) levels, and they were more prone to
be taking antithrombotic medication. Ninety-nineTABLE 1 Cardiovascular Risk Factors of the Study Population Stratiﬁ
All (n ¼ 678) No (n ¼ 60
Age, yrs 64.5  6.8 64.1  6.8
ESVEA 99 (14.6) 78 (12.9)
Female 281 (41.4) 252 (41.7)
Current smoking 314 (46.3) 272 (45.0)
Diabetes mellitus 75 (11.1) 63 (10.2)
Glucose, mmol/L 5.8  1.7 5.8  1.7
Systolic blood pressure, mm Hg 156.4  24.2 155.3  24
Diastolic blood pressure, mm Hg 90.9  10.9 90.6  11
CHA2DS2-VASc
0 141 (20.8) 135 (22.3)
1 164 (24.2) 151 (25.0)
2 189 (27.9) 163 (26.9)
$3 184 (27.1) 156 (25.8)
Total cholesterol, mmol/l 6.0  1.0 6.1  1.1
LDL-cholesterol, mmol/l 3.9  1.0 3.9  1.0
NT-proBNP, pmol/l 6.9 (3.6–13.8) 6.5 (3.5–13
Log (NT-proBNP) 2.0  1.1 1.9  1.1
C-reactive protein, mg/l 2.5 (1.1–4.6) 2.5 (1.1–4.6
Log (C-reactive protein) 0.9  1.1 0.8  1.1
Alcohol, units/week 13.0 (0–26) 13.0 (0–26)
Low level of physical activity 174 (25.9) 155 (25.8)
Body mass index, kg/m2 26.8  4.4 26.8  4.
Aspirin use 103 (15.2) 84 (13.9)
b-Blocker use 34 (5.0) 29 (4.8)
Diuretic use 121 (17.8) 102 (16.9)
ACE inhibitor use 32 (4.7) 26 (3.7)
Values are mean  SD, n (%), or median (Q1 to Q3). *p < 0.01. †p < 0.05. p values repo
overall within-group difference.
ACE ¼ angiotensin-converting enzyme; CHA2DS2-VASc¼ congestive heart failure, hype
attack, vascular disease, age 65 to 74 years, female; ESVEA ¼ excessive supraventricular
brain natriuretic peptide.subjects were classiﬁed as having ESVEA; 70 subjects
had >30 PACs/h daily, and 42 had runs of PACs with a
length greater than $20 PACs. Thirteen subjects had
both irregularities. Study subjects with ESVEA at
baseline shared many of the same baseline risk factors
as subjects who later developed ischemic stroke.
FOLLOW-UP AND ENDPOINTS. Ischemic stroke
occurred in 73 subjects, of whom 21 (29%) had ESVEA
at baseline. Subjects with ESVEA had 21.5 strokes/
1,000 person-years, and subjects without ESVEA had
7.4 strokes/1,000 person-years (hazard ratio [HR]:
2.07; 95% conﬁdence interval [CI]: 1.21 to 3.56) after
adjustment for age, sex, smoking, total cholesterol,
diabetes, body mass index, and systolic blood pres-
sure. Further adjustments for aspirin use and NT-
proBNP did not affect the results signiﬁcantly (HR:
2.02; 95% CI: 1.17 to 3.49). A total of 259 subjects died in
the follow-up period, and 287 subjects had a combined
outcome of death or stroke: 58.5 events/1,000 person-
years in subjects with ESVEA, and 32.7 events/1,000ed by the Occurrence of Ischemic Stroke and ESVEA at Baseline
Stroke ESVEA
5) Yes (n ¼ 73) No (n ¼ 579) Yes (n ¼ 99)
67.7  6.4* 64.0  6.8 67.6  6.3*
21 (28.8)* — —
29 (39.7) 246 (42.5) 35 (35.4)
42 (57.5)† 267 (46.1) 47 (47.5)
12 (16.5) 63 (10.9) 12 (12.1)
6.2  2.0 5.8  1.8 5.8  1.1
.3 165.5  21.6* 155.4  23.8 162.3  25.7*
.1 93.5  9.5† 90.7  11.1 92.1  10.0
* *
6 (8.2) 131 (22.6) 10 (10.1)
13 (17.8) 145 (25.0) 19 (19.2)
26 (35.6) 155 (26.8) 34 (34.3)
28 (38.4) 148 (25.6) 36 (36.4)
6.0  1.0 6.1  1.0 5.8  1.0†
3.9  0.9 3.9  0.9 3.6  1.0†
.0) 8.6 (5.2–21.9)* 6.3 (3.3–12.3) 12.4 (5.5–25.7)*
2.3  1.1* 1.9  1.1 2.6  1.1*
) 2.7 (1.2–4.6) 2.4 (1.1–4.5) 2.9 (0.9–6.2)
1.0  1.0 0.8  1.1 1.0  1.2
11.0 (4–27) 13.0 (3–27) 12.0 (0–24)
19 (26.4) 147 (25.6) 27 (27.6)
3 26.6  4.6 26.7  4.2 27.0  5.2
19 (26.0)* 81 (14.0) 22 (22.2)*
5 (6.8) 30 (5.2) 4 (4.0)
19 (26.0) 96 (16.6) 25 (25.3)*
6 (8.2) 27 (4.7) 5 (5.1)
rted are within-group differences. The p value of the CHA2DS2-VASc score is a test of
rtension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic
ectopic activity; LDL ¼ low-density protein; NT-proBNP ¼ N-terminal prohormone of
TABLE 3 Cox Regression Models Showing the Hazard Ratio of
ESVEA in Relation to Stroke and Death or Stroke, Where Atrial
Fibrillation is Modeled as a Time-Varying Exposure
Stroke Death or Stroke
ESVEA in Model 1* 2.28 (1.34–3.88)
p ¼ 0.002
1.38 (1.02–1.87)
p ¼ 0.036
ESVEA in Model 2† 2.00 (1.16-3.45)
p ¼ 0.013
1.35 (0.99–1.84)
p ¼ 0.053
Values are hazard ratio (95% conﬁdence interval). *Model 1: adjusted for age, sex,
and incident atrial ﬁbrillation. †Model 2: adjusted for additional stroke risk factors
(age, sex, incident atrial ﬁbrillation, smoking, total cholesterol, diabetes, body
mass index and systolic blood pressure).
ESVEA ¼ excessive supraventricular ectopic activity.
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236person-years in subjects without ESVEA (HR: 1.44;
95% CI: 1.06 to 1.95) after adjustment for age, sex,
smoking, total cholesterol, diabetes, body mass in-
dex, and systolic blood pressure. Further adjustment
for aspirin and NT-proBNP did not change the results
signiﬁcantly (HR, 1.38; 95% CI: 1.01 to 1.89). Seventy-
seven subjects were diagnosed with incident AF
during follow-up, and 18 of these subjects (23%) had
ESVEA at baseline.
RISK ASSOCIATED WITH ESVEA BEYOND AF. When
censoring subjects at time of AF, ischemic stroke
occurred more frequently in subjects with ESVEA
than in those without (19.9 vs. 7.2/1,000 patient-
years; p ¼ 0.0001).
In multivariate Cox models with censoring at time
of AF and after adjustment for relevant baseline risk
factors, ESVEA was associated with stroke and the
combined endpoint of death or stroke (Table 2).
ESVEA remained associated with stroke in fully
adjusted models when modeling AF as a time-varying
exposure; however, the combined endpoint of stroke
and death became borderline signiﬁcant (Table 3). In
a Fine-Gray competing risk model with AF and
death as competing risks and after adjusting for age
and sex, ESVEA remained correlated with stroke
(subdistribution hazard: 1.82; 95% CI: 1.03 to 3.22).
However, the results attenuated to insigniﬁcant
(subdistribution hazard: 1.60; 95% CI: 0.87 to 3.22)
after adjusting for additional stroke risk factors
(age, sex, smoking, total cholesterol, diabetes, body
mass index, and systolic blood pressure).
ESTIMATED RISK OF STROKE ASSOCIATED WITH
ESVEA. We calculated the absolute risk of stroke ac-
cording to the subjects’ CHA2DS2-VASc score at
baseline. A stepwise increase in the rates of stroke
was observed with increasing score, and a signiﬁ-
cantly higher risk was seen in the patients with
ESVEA, as illustrated in Figure 1 (p ¼ 0.0002). Subjects
with ESVEA and CHA2DS2-VASc score $2 had an ab-
solute risk of stroke equal to 2.4% per year.TABLE 2 Cox Regression Models Showing the Hazard Ratio of
ESVEA in Relation to Stroke and Death or Stroke, Where Subjects
are Censored at the Time of Atrial Fibrillation
Stroke Death or Stroke
ESVEA in Model 1* 2.16 (1.24–3.76)
p ¼ 0.007
1.54 (1.14–2.07)
p ¼ 0.004
ESVEA in Model 2† 1.96 (1.10–3.49)
p ¼ 0.022
1.51 (1.11–2.05)
p ¼ 0.008
Values are hazard ratio (95% conﬁdence interval). *Model 1: adjusted for age and
sex. †Model 2: adjusted for additional stroke risk factors (age, sex, smoking, total
cholesterol, diabetes, body mass index, and systolic blood pressure).
ESVEA ¼ excessive supraventricular ectopic activity.The risk of stroke associated with ESVEA was
greater in patients >65 years of age (Table 4) than in
patients #65 years of age. The Kaplan-Meier survival
function of the 2 groups is depicted in Figure 2.
VARIABILITY OF ATRIAL ECTOPY. ESVEA was clas-
siﬁed as $30 PACs/h, and we assessed the day-to-day
variability of having $30 PACs/h. Recordings for each
individual were compared for 2 different days against
the 48-h monitoring period. This resulted in kappa
values for having $30 PACs/h of 0.90 (95% CI: 0.83 to
0.98) and 0.89 (95% CI: 0.82 to 0.97), respectively.
Thus, if a person has excessive PACs in a 24-h ex-
amination, there is a very high probability of having
the same ﬁnding on a following day.
SENSITIVITY ANALYSIS. A nonlinear association
between number and runs of PACs with stroke was
observed (Figure 3). In univariate analysis, a dichot-
omized variable for top decile for PACs/hour and
runs of PACs each correlated with stroke (HR: 2.24;
95% CI: 1.23 to 4.09; and HR: 2.82; 95% CI: 1.44 to
5.5; respectively). When adjusting for conventional
risk factors (age, sex, smoking, total cholesterol,
diabetes, body mass index, and systolic blood pres-
sure), runs of PAC remained associated with stroke
(HR: 2.26; 95% CI: 1.1 to 4.64), whereas PACs/hour
did not (HR: 1.60; 95% CI: 0.86 to 3.02). In a sub-
analysis, we tested subjects with runs ranging from
20 to 50 PACs to determine whether shorter runs
lasting <0.5 min had an impact on the risk of stroke.
Both in univariate analysis (HR: 2.61; 95% CI: 1.19 to
5.70) and after adjusting for gender and age (HR:
2.43; 95% CI: 1.11 to 5.33), the results remained
signiﬁcant.
The positive and negative predictive values of
ESVEA in relation to ischemic stroke were 21.2% and
91%, respectively. To assess whether ESVEA adds
prognostic value to the Framingham Stroke Risk
Score, we calculated the Framingham Stroke Risk
Score of all subjects. With ischemic stroke as the
endpoint, the HR for each increase of 1 point was 1.20
TABLE 4 Number of Strokes per 1,000 Person-Years in Relation to ESVEA
and Age Groups
Age Group, yrs
Presence (þ) or
Absence ()
of ESVEA n
Stroke,
n (%)*
Time at
Risk (yrs)
Strokes/1,000
Person-Yrs
(95% CI) p Value†
#65  ESVEA 391 25 (6.4) 5,045 5.0 (3.3–7.3) Reference
n ¼ 438 þ ESVEA 47 5 (10.6) 559 8.9 (3.7–21.5) 0.2086
>65  ESVEA 188 27 (14.4%) 1,978 13.6 (9.4–19.9) Reference
n ¼ 240 þ ESVEA 52 16 (30.8%) 415 38.5 (23.6–62.9) 0.0007
*Indicates % of number in the row. †Log-rank test for equality of survivor function.
CI ¼ conﬁdence interval; ESVEA ¼ excessive supraventricular ectopic activity.
FIGURE 1 Incidence of Stroke per 1,000 Patient-Years According to ESVEA and
CHA2DS2-VASc score
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A stepwise increase in the rates of stroke was observed with increasing CHA2DS2-VASc
(congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous
stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score and
a signiﬁcantly higher risk in the patients with excessive supraventricular ectopic activity
(ESVEA) (p ¼ 0.0002).
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237(95% CI: 1.14 to 1.28; p < 0.000). With entrance of
ESVEA to the model, ESVEA maintained prognostic
value for ischemic stroke (HR: 2.10; 95% CI: 1.25 to
3.56; p ¼ 0.005). A likelihood ratio test including
ESVEA showed that the model improved signiﬁcantly
(likelihood ratio chi-square ¼ 6.88; p ¼ 0.0087).
DISCUSSION
MAJOR FINDINGS. The principal ﬁnding of this study
is that in middle-aged and older study subjects with
no apparent heart disease, ESVEA is associated with
an increased risk of ischemic stroke. The study also
shows a strong correlation between ESVEA and
ischemic stroke beyond AF. Both in censoring anal-
ysis and when modeling AF as a time-varying expo-
sure, the results were signiﬁcantly associated with
ischemic stroke in fully adjusted models. In a
competing risk analysis with death and AF as
competing events, the association between ESVEA
and ischemic stroke attenuated to insigniﬁcant. In all
likelihood, this ﬁnding demonstrates that subjects
with ESVEA, compared with those without, have a
greater risk of dying or developing AF before they
have a stroke. However, 82% of the subjects with
ESVEA did not develop clinical AF during the follow-
up of 15 years, and only a minority (14.3%) among the
subjects with ESVEA who had a stroke also had a
diagnosis of incident AF. The absolute risk of stroke
in subjects with ESVEA and a CHA2DS2-VASc score $2
was 2.4% per year, which is equivalent to patients
with AF and a CHA2DS2-VASc score of 2 (20,21). This is
classiﬁed as a high risk, and it normally warrants
anticoagulation in patients with AF. Addition of
ESVEA to the Framingham Stroke Risk Score showed
that ESVEA maintained prognostic value. Thus
ESVEA may be considered a risk factor for ischemic
stroke.
VALUE OF ESVEA AS A NOVEL METHOD TO PREDICT
STROKE. Traditionally, the only arrhythmias that are
viewed as causing ischemic stroke are manifest AF or
atrial ﬂutter (22). This study suggests that other
atrial electric instabilities, such as ESVEA and even
short runs of 20 to 50 PACs, can account for some
proportion of cryptogenic strokes. Earlier research
investigating the causes of unexplained ischemic
stroke supports this hypothesis (23,24). Kamel et al.
(23) demonstrated an independent association be-
tween paroxysmal supraventricular tachycardia and
subsequent ischemic stroke (HR: 2.10; 95% CI: 1.69 to
2.62) in a large, demographically diverse cohort
with no earlier diagnosis of AF. In a similar fashion,
a study by Healey et al. (24) showed a link bet-
ween subclinical AF, deﬁned as episodes of atrialrate >190 beats/min for >6 min, and the risk of
ischemic stroke in patients without clinical AF and no
earlier events of stroke (HR: 2.50; 95% CI: 1.28 to
4.89). In another study, Ofoma et al. (25) reported
that a ﬁnding of PAC and premature ventricular
contraction on a 2-min ECG strip was associated with
an increased risk of ischemic stroke. However, the
associations attenuated into insigniﬁcant after
adjustment for coexisting risk factors. The in-
consistencies between this study and ours may reﬂect
FIGURE 2 Kaplan-Meier Survival Estimate of Stroke-Free Survival Stratiﬁed on Age-Groups and ESVEA
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The risk of stroke associated with excessive supraventricular ectopic activity (ESVEA) was greater in patients >65 years of age (p ¼ 0.0007),
but not in patients #65 years of age (p ¼ 0.2086).
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238the different populations studied or the method of
detection of PAC or premature ventricular contrac-
tion. The identiﬁcation of subjects with increased
ectopy on the basis of a 2-min ECG may have some
limitations compared with 48 h of continuous ECG
recording.
The possible pathophysiological mechanism by
which excessive AE may contribute to increase the
risk of ischemic stroke is unclear. The most likely
explanation is that increased ectopic activity pre-
cedes undiagnosed incident AF and thus enhances
the possibility of cardioembolism and stroke. Koch-
häuser et al. (26) demonstrated that increased ectopic
activity (>14.1/h) and supraventricular runs (>0.2 h)
in patients with cryptogenic stroke are associated
with a high risk of future AF (relative risk: 4.0; 95%
CI: 1.1 to 14.6). A similar study by Wallmann et al. (27)
showed that frequent PAC (>70/24 h) represents a
risk factor, independent of traditional risk factors, for
paroxysmal AF (odds ratio: 6.6; 95% CI: 1.6 to 28.2) in
patients with recently diagnosed ischemic stroke.Another possibility could be that increased AE is a
marker of more severe hypertension, diabetes, phys-
ical inactivity, or lipid metabolism abnormality (28),
thus signifying an increased vascular risk proﬁle and
an increased probability of stroke in these subjects. In
that case, ESVEA may identify patients with more
target organ damage.
A third and hypothetical mechanism could be that
interactions between coexisting risk factors such as
hypertension and smoking, in addition to increased
number and runs of PACs, may lead to dilation of the
left atrium, stasis in the left atrial appendage, ﬁbrosis,
and endothelial dysfunction, eventually resulting in
a hypercoagulable state comparable to that present
in AF (29–32). The different hypotheses are not
mutually exclusive and may coexist in patients
(Central Illustration).
DETECTION OF AF. AF is a well-established risk factor
for ischemic stroke and thromboembolisms. How-
ever, a shortcoming of the short-term ECG-recording
FIGURE 3 Incidence of Stroke per 1,000 Patient-Years in Relation to Average Hourly PACs and Length of Runs of PACs
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A nonlinear association between number and runs of premature atrial contractions (PACs) with stroke was observed in these patients.
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239for detecting AF is the rarity of episodes. Recent
prospective studies in search of cardiovascular
causes behind cryptogenic stroke have demon-
strated a better diagnostic yield of AF with pro-
longed ECG recording. A study by Gladstone et al.
(8) used a 30-day event-triggered loop recorder
and had a detection rate of 16.1% (3.2% in the
control group). A comparable study by Sanna et al.
(5) used an insertable cardiac monitor with the
primary endpoint being detection of AF within 6
months, and it had a detection rate of 8.9% (1.4%
in control group). Both studies were using control
groups with conventional follow-up including Hol-
ter monitoring (5,8). The increased detection rate
with prolonged ECG monitoring is reﬂected in the
latest guideline from the American Stroke Associa-
tion. This organization recommends rhythm moni-
toring for up to 30 days within 6 months of an
index ischemic stroke or transient ischemic
attack compared with the previous recommenda-
tion of 24 h or more (22,33). However, the exten-
sive diagnostics are time consuming for both
patients and doctors, and many of these patientsmay have ESVEA and be considered at risk from
the outset.
The advantage of using ESVEA as a novel method
to predict stroke would be that ESVEA is more
frequent than episodes of AF. We have shown excel-
lent day-to-day reproducibility for detecting ESVEA,
and ESVEA may therefore serve as an early and more
consistent ﬁnding as compared with rare episodes of
AF. Future studies are needed to evaluate whether
intensive risk factor modiﬁcation in these patients
could improve the outcome, as shown in patients
with AF and paroxysmal AF (34).
STUDY LIMITATIONS. All causation between PAC
and ischemic stroke has not been documented.
Subjects with manifest or previous heart disease
were excluded from this study, and we cannot
dismiss the possibility that ESVEA is an epiphe-
nomenon of undetected heart diseases, which in-
crease the risk of stroke independently of the ectopic
activity.
Although we adjust for several known covariates
associated with ischemic stroke in the regression
CENTRAL ILLUSTRATION Excessive Atrial Ectopy and Other Risk Factors in Relation to Ischemic Stroke
Larsen, B.S. et al. J Am Coll Cardiol. 2015; 66(3):232–41.
Excessive atrial ectopy and short atrial runs are associated with an increased risk of ischemic stroke beyond atrial ﬁbrillation. However, the
exact mechanism is not known and may be caused by undiscovered incident atrial ﬁbrillation or an increased vascular risk proﬁle.
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke or transient ischemic attack,
vascular disease, age 65 to 74 years, female.
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240analyses, residual confounding may have inﬂuenced
the results. Because echocardiography and carotid
ultrasound examinations were not performed in these
subjects, we could not account for structural cardiac
abnormalities and possible carotid plaques. However,
NT-proBNP values were almost in the normal range in
subjects with ESVEA, and analyses adjusting for this
factor did not change the results signiﬁcantly. In
addition, other unknown confounding factors (e.g.,
sleep apnea) could trigger paroxysmal AF and stroke
in some cases in subjects with risk factors. Hence
some degree of residual confounding cannot be
excluded, especially with regard to the composite
endpoint of stroke and death.
The follow-up period of up to 15 years in-
creases the number of events and thus increases the
power to detect associations. Nevertheless, because
risk factors change over the course of a decade, a
direct cause and effect relationship is difﬁcult to
demonstrate.
In regression analysis using PACs and runs of PACs
as continuous variables, we could not establish a
“dose-response” association. We previously reportedlinear associations between PACs or runs of PACs and
AF (11), but it seems that PACs and runs must be more
extreme to constitute a risk for stroke. However, study
subjects in the top decile carried a worse prognosis in
both hourly PACs and runs of PACs. Although the
deﬁnition of ESVEA was made on the basis of previ-
ously published reports, this arbitrarily deﬁned cutoff
point needs to prove its value in other populations.
CONCLUSIONS
In this middle-aged and older population, ESVEA was
associated with an increased risk of ischemic stroke
beyond manifest AF. Stroke was more often the ﬁrst
clinical presentation, rather than incident AF. ESVEA
is a clinically stable and consistent ﬁnding that seems
to confer a stroke risk comparable to that of AF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: PACs are
often asymptomatic and considered benign, but frequent
or longer runs of PACs (other than AF or atrial ﬂutter) are
associated with an increased risk of ischemic stroke in
middle-aged and older patients.
TRANSLATIONAL OUTLOOK: More research is needed
to determine whether the risk of stroke in patients with
high-grade AE is related to thrombogenic atrial disease or
later development of AF, and randomized trials should
assess whether antithrombotic treatments or other risk
factor modiﬁcations reduce the risk of ischemic stroke in
patients with atrial ectopy other than AF or atrial ﬂutter.
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